Topotecan

Elraglusib, a GSK-3β inhibitor, has been granted rare pediatric disease designation by the FDA for treating Ewing sarcoma, highlighting the need for new therapies.

Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, receives FDA Rare Pediatric Disease Designation for Ewing sarcoma (EWS) treatment.

Researchers have identified that cancer cells evade Top1 inhibitor treatments by activating the DNA repair enzyme TDP1, highlighting a novel resistance mechanism.

• Researchers have identified new drug combinations that enhance immunotherapy effectiveness in lung cancer, particularly in tumors resistant to standard treatments. • A study shows that combining ATR inhibitors with topotecan improves outcomes for relapsed small cell lung cancer by activating the immune system. • Combining KRAS G12C and SHP2 inhibitors with immunotherapy significantly reduced tumor size and recurrence in mice with lung cancer. • Dual checkpoint inhibitors may benefit non-small cell lung cancer patients with STK11 and KEAP1 mutations, improving response rates and survival.

• Sidney Hecht received the Arizona Bioscience Pioneer Award for Lifetime Achievement for merging biology and chemistry to improve human health. • Hecht's research at ASU's Biodesign Center focuses on mitochondrial disorders, particularly Friedreich’s ataxia, a genetic neuromuscular disease. • Hecht played a key role in developing Hycamtin, a chemotherapy drug for ovarian and lung cancer, and studied the anti-tumor agent Bleomycin. • His center has developed compounds that redirect electrons in dysfunctional respiratory chains, with one in clinical trials for Friedreich’s ataxia.